Tempus Validates PurIST Algorithm for Personalized Pancreatic Cancer Treatment Selection in Largest Real-World Study
核心洞察
Tempus AI published validation data in JCO Precision Oncology for its PurIST (搜索) algorithm, analyzing 931 patients with advanced pancreatic ductal adenocarcinoma (搜索) to guide first-line chemotherapy selection.
The RNA-based diagnostic classifies tumors as classical or basal subtypes, with classical subtype patients showing significantly longer median overall survival of 11.8 months versus 7.0 months for basal subtypes when treated with FOLFIRINOX.
Classical subtype patients with good performance status demonstrated a 33% relative risk reduction in death when treated with FOLFIRINOX compared to gemcitabine plus nab-paclitaxel, establishing PurIST (搜索) as both prognostic and predictive biomarker.
Tempus AI has published the largest real-world validation study to date for its PurIST (搜索) algorithmic diagnostic in JCO Precision Oncology, demonstrating the test's ability to guide first-line chemotherapy selection and improve outcomes for patients with advanced pancreatic ductal adenocarcinoma (搜索) (PDAC (搜索)). The study analyzed 931 patients and establishes PurIST as both a prognostic and predictive biomarker for this challenging malignancy.
Clinical Validation in Real-World Setting
The Tempus-led study utilized the company's xR RNA sequencing platform to assign PurIST (搜索) subtypes to patients with advanced PDAC (搜索). The RNA-based algorithm classifies tumors as either "classical" or "basal" subtypes, enabling clinicians to personalize treatment selection between the two most common first-line chemotherapy regimens: FOLFIRINOX (FFX) and gemcitabine plus nab-paclitaxel (GnP).
Pancreatic cancer (搜索) remains one of the most lethal malignancies, with limited therapeutic options and a five-year survival rate of just 12%. For patients with advanced, unresectable PDAC (搜索), the variable efficacy of existing treatments has left clinicians without robust biomarkers to guide optimal therapy selection until now.
Significant Survival Benefits Demonstrated
The study's findings reveal compelling evidence for PurIST (搜索)'s clinical utility across two key dimensions. As a prognostic biomarker, among patients treated with FFX (N=536), those with the classical subtype demonstrated significantly longer median overall survival of 11.8 months compared to 7.0 months for basal subtype patients (Hazard Ratio [HR]=1.86; p<0.001).
The predictive value proved equally significant. In patients with the classical subtype and good performance status (ECOG 0 or 1, N=311), treatment with FFX was associated with a 33% relative risk reduction in death compared to GnP (HR=0.67; p<0.009). Notably, no comparable benefit was observed in basal subtype patients, highlighting the algorithm's ability to identify patients most likely to benefit from specific therapies.
Addressing Critical Unmet Medical Need
"Pancreatic cancer (搜索) is a challenging disease, and the ability to match patients to the most effective first-line therapy is critical," said Ezra Cohen, MD, Chief Medical Officer, Oncology at Tempus. "Prior research has suggested that certain molecular subtypes are associated with distinct prognoses and responses to therapy, but until now, large-scale real-world validation in a clinical setting has been lacking. Our study demonstrates that PurIST (搜索) subtyping enables a biomarker-driven approach to therapy selection, addressing a major unmet need in the management of pancreatic cancer."
The development of PurIST (搜索) represents a collaboration between Tempus and GeneCentric (搜索), combining advanced AI capabilities with clinical expertise to create a clinically validated diagnostic tool. Michael Milburn, PhD, President and CEO of GeneCentric and co-author on the publication, emphasized the significance of this advancement: "PurIST is a step forward for pancreatic cancer (搜索) molecular testing, giving healthcare providers a new tool to better inform personalized treatment options for this devastating disease."
Integration into Clinical Practice
The validation study provides the foundation for integrating PurIST (搜索) into routine clinical care for patients with advanced PDAC (搜索). By leveraging Tempus' multimodal data platform and RNA sequencing capabilities, the test offers clinicians an evidence-based approach to treatment selection that could significantly impact patient outcomes in a disease area with historically limited therapeutic options.
The publication in JCO Precision Oncology represents a milestone in precision oncology for pancreatic cancer (搜索), providing healthcare providers with the largest real-world evidence base to support biomarker-driven treatment decisions in this challenging malignancy.